First human test of spinal injection for rare brain disease
NCT ID NCT04539041
Summary
This study tested the safety of a new drug, NIO752, given as an injection into the spinal fluid for people with progressive supranuclear palsy (PSP), a rare and serious brain disorder. The main goal was to see if the treatment was safe and how the body processes it. About 59 participants received either the drug or a placebo over several months and were closely monitored.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY(PSP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Novartis Investigative Site
Montreal, Quebec, H2X 1R9, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3A 2B4, Canada
-
Novartis Investigative Site
Bonn, North Rhine-Westphalia, 53127, Germany
-
Novartis Investigative Site
Düsseldorf, 40225, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
München, 81377, Germany
-
Novartis Investigative Site
Tübingen, 72076, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
Southampton, SO16 6YD, United Kingdom
-
University of California San Diego
La Jolla, California, 92037, United States
-
Vanderbilt University Medical CenterX
Nashville, Tennessee, 37221, United States
Conditions
Explore the condition pages connected to this study.